Chan-Palay V
Neurology Clinic, University Hospital, Zurich, Switzerland.
Psychopharmacology (Berl). 1992;106 Suppl:S137-9. doi: 10.1007/BF02246259.
Depression is common in patients with senile dementia of the Alzheimer type (SDAT) and may precede the onset of the dementia; the underlying biological and neurotransmitter mechanisms may be common to both diseases, so far as norepinephrine lesions are concerned. The major routes of metabolism of amines in the brain utilize the monoamine oxidase (MAO) enzymes. Due to the consistent severity of norepinephrine lesions in the locus coeruleus of patients with pre-senile dementia or SDAT and the fact that MAO-A enzyme is the major metabolizing enzyme present in the locus coeruleus in man, the new specific, reversible MAO-A inhibitors may have a place in the treatment of depression associated with SDAT.
抑郁症在阿尔茨海默型老年痴呆症(SDAT)患者中很常见,且可能在痴呆症发作之前出现;就去甲肾上腺素损伤而言,这两种疾病潜在的生物学和神经递质机制可能相同。大脑中胺类的主要代谢途径利用单胺氧化酶(MAO)。由于早老性痴呆症患者或SDAT患者蓝斑中去甲肾上腺素损伤的严重程度一致,且MAO - A酶是人类蓝斑中主要的代谢酶,新型特异性、可逆性MAO - A抑制剂可能在治疗与SDAT相关的抑郁症中占有一席之地。